Optimising utilisation of GLASS data to inform cross-border antimicrobial resistance strategy is a priority

Lancet Reg Health Am. 2023 Dec 22:29:100655. doi: 10.1016/j.lana.2023.100655. eCollection 2024 Jan.

Scott John Charles Pallett^{1

2}, Esmita Charani^{3

4}, Georgia Lamb², Andrea Mazzella⁵, Saleh A Alqahtani^{6

7}, Luke Stephen Prockter Moore^{2

8}

¹ Centre of Defence Pathology, Royal Centre for Defence Medicine, Edgbaston, Birmingham B15 2WB, UK.
² Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK.
³ Division of Infectious Diseases and HIV Medicine, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
⁴ Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
⁵ Infection and Immunity Clinical Academic Group, St George's University Hospitals NHS Foundation Trust, Blackshaw Road, London SW17 0QT, UK.
⁶ Division of Gastroenterology & Hepatology, Johns Hopkins University, Baltimore, MD, United States of America.
⁷ Organ Transplant Centre of Excellence, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
⁸ National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK.

No abstract available